ZA200604451B - Pharmaceutical composition for oral administration of a pyrazole-3-carboxamide derivative - Google Patents
Pharmaceutical composition for oral administration of a pyrazole-3-carboxamide derivative Download PDFInfo
- Publication number
- ZA200604451B ZA200604451B ZA200604451A ZA200604451A ZA200604451B ZA 200604451 B ZA200604451 B ZA 200604451B ZA 200604451 A ZA200604451 A ZA 200604451A ZA 200604451 A ZA200604451 A ZA 200604451A ZA 200604451 B ZA200604451 B ZA 200604451B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- composition according
- pyrazole
- carboxamide
- propylene glycol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 30
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 claims description 37
- 239000004094 surface-active agent Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 18
- 239000006184 cosolvent Substances 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 14
- -1 oleoyl macrogol Chemical compound 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- 125000005456 glyceride group Chemical group 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 7
- 235000019438 castor oil Nutrition 0.000 claims description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 7
- 229960003511 macrogol Drugs 0.000 claims description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 7
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 4
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 3
- HMXDWDSNPRNUKI-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide Chemical compound CCC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 HMXDWDSNPRNUKI-UHFFFAOYSA-N 0.000 claims description 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- FZTHHIGKHFQAKY-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl decanoate Chemical compound CCCCCCCCCC(=O)OC(C)COC(=O)CCCCCCC FZTHHIGKHFQAKY-UHFFFAOYSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- FSVSNKCOMJVGLM-UHFFFAOYSA-N octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O FSVSNKCOMJVGLM-UHFFFAOYSA-N 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- OTFKMOPPDBDJAI-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-ethyl-1h-pyrazole-5-carboxamide Chemical compound CCC1=C(C(N)=O)NN=C1C1=CC=C(Cl)C=C1Cl OTFKMOPPDBDJAI-UHFFFAOYSA-N 0.000 claims 2
- OYNGQUAKHHLPFR-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=NNC(C=2C(=CC(Cl)=CC=2)Cl)=C1C OYNGQUAKHHLPFR-UHFFFAOYSA-N 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 18
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 235000012093 Myrtus ugni Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 244000061461 Tema Species 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0313259A FR2861992B1 (fr) | 2003-11-10 | 2003-11-10 | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200604451B true ZA200604451B (en) | 2007-10-31 |
Family
ID=34508418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604451A ZA200604451B (en) | 2003-11-10 | 2004-11-09 | Pharmaceutical composition for oral administration of a pyrazole-3-carboxamide derivative |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20060264469A1 (xx) |
| EP (1) | EP1691808B1 (xx) |
| JP (1) | JP4767171B2 (xx) |
| KR (1) | KR20060108668A (xx) |
| CN (1) | CN100528158C (xx) |
| AR (1) | AR047237A1 (xx) |
| AT (1) | ATE429227T1 (xx) |
| AU (1) | AU2004289086A1 (xx) |
| BR (1) | BRPI0416341A (xx) |
| CA (1) | CA2544413A1 (xx) |
| CY (1) | CY1110478T1 (xx) |
| DE (1) | DE602004020797D1 (xx) |
| DK (1) | DK1691808T3 (xx) |
| ES (1) | ES2325373T3 (xx) |
| FR (1) | FR2861992B1 (xx) |
| HK (1) | HK1102021A1 (xx) |
| HR (1) | HRP20090393T1 (xx) |
| IL (1) | IL175556A (xx) |
| MA (1) | MA28419B1 (xx) |
| NO (1) | NO20062609L (xx) |
| NZ (1) | NZ547763A (xx) |
| PL (1) | PL1691808T3 (xx) |
| PT (1) | PT1691808E (xx) |
| RU (1) | RU2321404C1 (xx) |
| SI (1) | SI1691808T1 (xx) |
| TW (1) | TWI280129B (xx) |
| WO (1) | WO2005046690A1 (xx) |
| ZA (1) | ZA200604451B (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1880715A1 (en) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| PL2192893T3 (pl) * | 2007-08-21 | 2015-12-31 | Basilea Pharmaceutica Ag | Kompozycja przeciwgrzybicza |
| MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| US20130317117A1 (en) * | 2010-11-24 | 2013-11-28 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059691A (en) * | 1990-01-22 | 1991-10-22 | American Cyanamid Company | N-((dialkylamino)methylene)-substituted pyrazolo (1,5-A)-pyrimidine-3-carboxamides and N-((dialkylamino)methylene)-substituted-4,5-dihydropyrazolo-(1,5-A)-pyrimidine-3-carboxamides |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| DE69435104D1 (de) * | 1993-09-28 | 2008-07-31 | Scherer Gmbh R P | Herstellung von Weichgelatinekapseln |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| AU692255B2 (en) * | 1995-04-24 | 1998-06-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
| EP0825849A1 (en) * | 1995-05-19 | 1998-03-04 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
| US5993858A (en) * | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| US6197774B1 (en) * | 1997-03-14 | 2001-03-06 | Otsuka Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| FR2761265B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| US6617426B1 (en) * | 1999-06-22 | 2003-09-09 | Merck & Co Inc | Cysteinyl protease inhibitors |
| JP2001151669A (ja) * | 1999-11-24 | 2001-06-05 | Nippon Kayaku Co Ltd | 経口用自己乳化製剤 |
| EA006402B1 (ru) * | 1999-12-23 | 2005-12-29 | Пфайзер Продактс Инк. | Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты) |
| GB0001928D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| FR2831883B1 (fr) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| WO2003074027A2 (en) * | 2002-03-01 | 2003-09-12 | Novagali Pharma Sa | Self emulsifying drug delivery systems for poorly soluble drugs |
| GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
-
2003
- 2003-11-10 FR FR0313259A patent/FR2861992B1/fr not_active Expired - Fee Related
-
2004
- 2004-11-08 AR ARP040104109A patent/AR047237A1/es unknown
- 2004-11-08 TW TW093134037A patent/TWI280129B/zh not_active IP Right Cessation
- 2004-11-09 DK DK04805418T patent/DK1691808T3/da active
- 2004-11-09 ZA ZA200604451A patent/ZA200604451B/en unknown
- 2004-11-09 AU AU2004289086A patent/AU2004289086A1/en not_active Abandoned
- 2004-11-09 CN CNB2004800367848A patent/CN100528158C/zh not_active Expired - Fee Related
- 2004-11-09 SI SI200431173T patent/SI1691808T1/sl unknown
- 2004-11-09 BR BRPI0416341-9A patent/BRPI0416341A/pt not_active IP Right Cessation
- 2004-11-09 WO PCT/FR2004/002875 patent/WO2005046690A1/fr active Search and Examination
- 2004-11-09 RU RU2006120447/15A patent/RU2321404C1/ru not_active IP Right Cessation
- 2004-11-09 PL PL04805418T patent/PL1691808T3/pl unknown
- 2004-11-09 DE DE602004020797T patent/DE602004020797D1/de active Active
- 2004-11-09 NZ NZ547763A patent/NZ547763A/xx unknown
- 2004-11-09 CA CA002544413A patent/CA2544413A1/fr not_active Abandoned
- 2004-11-09 PT PT04805418T patent/PT1691808E/pt unknown
- 2004-11-09 ES ES04805418T patent/ES2325373T3/es active Active
- 2004-11-09 EP EP04805418A patent/EP1691808B1/fr active Active
- 2004-11-09 AT AT04805418T patent/ATE429227T1/de active
- 2004-11-09 JP JP2006538894A patent/JP4767171B2/ja not_active Expired - Fee Related
- 2004-11-09 KR KR1020067009010A patent/KR20060108668A/ko not_active Application Discontinuation
-
2006
- 2006-05-08 MA MA29012A patent/MA28419B1/fr unknown
- 2006-05-08 US US11/382,111 patent/US20060264469A1/en not_active Abandoned
- 2006-05-09 IL IL175556A patent/IL175556A/en not_active IP Right Cessation
- 2006-06-06 NO NO20062609A patent/NO20062609L/no not_active Application Discontinuation
-
2007
- 2007-06-25 HK HK07106763.5A patent/HK1102021A1/xx not_active IP Right Cessation
-
2008
- 2008-09-09 US US12/206,884 patent/US20090004261A1/en not_active Abandoned
-
2009
- 2009-07-10 HR HR20090393T patent/HRP20090393T1/xx unknown
- 2009-07-21 CY CY20091100777T patent/CY1110478T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20070084531A (ko) | 치환된 아미드의 경구 투여용 액체 및 반고체 약제학적제형 | |
| JP2002505271A (ja) | サイクロスポリン類またはマクロライド含有エマルジョン前濃縮物 | |
| US20220071983A1 (en) | Pharmaceutical Composition | |
| US8673351B2 (en) | Crystallization inhibitor and its use in gelatin capsules | |
| US20090004261A1 (en) | Pharmaceutical composition for oral administration of a pyrazole-3-carboxamide derivative | |
| EP2192893B1 (en) | Antifungal composition | |
| KR101928589B1 (ko) | 알리스포리비르를 포함하는 제약 조성물 | |
| EP1498123A1 (en) | Emulsifying systems containing azetidine derivatives | |
| JP2003521495A (ja) | テルビナフィン含有医薬組成物 | |
| MXPA06005247A (es) | Composicion farmaceutica destinada a la administracion oral de un derivado de pirazol-3-carboxamida | |
| KR20220139513A (ko) | 자가유화형 나노에멀전을 이용한 경구 투여 제제 | |
| Hasan et al. | International Journal of Advanced Pharmaceutics |